Novo Nordisk's CagriSema: promising but not perfect Abdullah Melhim, MD, DABOM posted on the topic LinkedIn 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Larvol Delta Buy Cagrilintide 5mg 10mg Third Party Tested BioEdge Peptides